Bladder Cancer Awareness Month 2024
Description
Over the past few decades, bladder cancer standard of care has not changed, with platinum-based chemotherapy and BCG as the core pillars of care. The last 12 months have seen two new regimens approved for frontline locally advanced / metastatic urothelial and one new treatment approved for BCG-unresponsive CIS NMIBC, significantly improving survival outcomes for patients. Many other clinical programs have continued progressing, ushering in a new wave of novel, targeted, and potentially more tolerable bladder cancer treatments.
In this Bladder Cancer Awareness Month special episode of Axiom Catalyst, Andrew Kassin and Kiana Ziadkhanpour interview Dr. Petros Grivas, a thought-leading GU Medical Oncologist of University of Washington and Fred Hutchinson Cancer Center, to discuss innovative bladder cancer treatments, changing treatment practices, and patient risk factors.
We are honored to continue spreading awareness for bladder cancer to help patients around the world! #BladderCancerAwarenessMonth2024 #AxiomThinkTank
United States
